Hormonal chemotherapy for hormone-refractory prostate cancer

To our knowledge, no standard chemotherapy for patients with hormone-refractory prostate cancer (HRPC) has been established. Since most patients with HRPC are elderly and have bone metastasis, cytotoxic chemotherapy causes them to be at high risk for myelosuppression. Therefore, chemotherapeutic age...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Hinyokika kiyo. Acta urologica Japonica. - 1962. - 48(2002), 11 vom: 03. Nov., Seite 713-8
1. Verfasser:	Nishimura, Kazuo (VerfasserIn)
Weitere Verfasser:	Nakai, Yasutomo, Shimizu, Kiyonori, Tokizane, Takashi, Arai, Yasuyuki, Inoue, Hitoshi, Takaha, Natsuki, Nonomura, Norio, Okuyama, Akihiko, Kamoi, Kazumi, Ukimura, Osamu, Miki, Tsuneharu, Koide, Takuo, Ichikawa, Yasuji, Nishimura, Kenji, Sugao, Hideki, Yamaguchi, Seiji, Takatera, Hiroshi, Uchida, Kinya, Miura, Hidenobu
Format:	Aufsatz
Sprache:	Japanese
Veröffentlicht:	2002
Zugriff auf das übergeordnete Werk:	Hinyokika kiyo. Acta urologica Japonica
Schlagworte:	Clinical Trial English Abstract Journal Article Multicenter Study Review Antineoplastic Agents, Hormonal Drug Combinations UFT(R) drug Tegafur 1548R74NSZ mehr... Estramustine 35LT29625A Uracil 56HH86ZVCT Dexamethasone 7S5I7G3JQL Cyclophosphamide 8N3DW7272P